No Data
No Data
JACOBIO-B: 2024 INTERIM REPORT
Jiakangsi-B (01167.HK): The company received the first payment for the exclusive license agreement with shanghai allist pharmaceuticals co., ltd. on GLECIRASIB and JAB-3312, as well as partial compensation for research and development expenses and other p
Grants of September 27th, Akesi-B (01167.HK) announced an exclusive license agreement with shanghai allist pharmaceuticals co., ltd. for Glecirasib and JAB-3312. The Company's subsidiary, Beijing Akesi New Drug Development Co., Ltd. (an indirectly-held non-wholly-owned subsidiary of the Company), has received an amount of approximately RMB 0.173 billion on August 30, 2024 from shanghai allist pharmaceuticals co., ltd. for the external license agreement on KRAS G12C inhibitor Glecirasib (JAB-21822) and SHP2 variant inhibitor JAB-3312, including an initial payment.
Jacobio Pharmaceuticals Group Cancer Drug's IND Application Gets NDMA's Nod
Hong Kong stock anomaly | Juhuasuan-B (01167) rose more than 4% at the end of the day. Pan-KRAS inhibitors approved for clinical trials in the usa.
Jiakuosi-B(01167) rose more than 4% in the final trading session, as of the time of writing, it rose 2.96%, to 1.74 Hong Kong dollars, with a turnover of 4.7074 million Hong Kong dollars.
Express News | Jacobio Pharmaceuticals - Got Investigational New Drug Approval From U.S. FDA for Pan-Kras Inhibitor Jab-23E73
JACOBIO-B: (1) INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED JUNE 30, 2024;(2) RESIGNATION OF NON-EXECUTIVE DIRECTOR; AND(3) CHANGE IN THE COMPOSITION OF THE REMUNERATIONCOMMITTEE AND THE NOMINATION COMMITTEE
No Data
No Data